X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SANOFI INDIA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SANOFI INDIA CIPLA/
SANOFI INDIA
 
P/E (TTM) x 44.9 33.3 135.0% View Chart
P/BV x 3.9 6.3 60.8% View Chart
Dividend Yield % 0.3 1.4 23.4%  

Financials

 CIPLA   SANOFI INDIA
EQUITY SHARE DATA
    CIPLA
Mar-17
SANOFI INDIA
Dec-16
CIPLA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6224,560 13.6%   
Low Rs4584,400 10.4%   
Sales per share (Unadj.) Rs181.91,028.5 17.7%  
Earnings per share (Unadj.) Rs12.9129.0 10.0%  
Cash flow per share (Unadj.) Rs29.3186.0 15.8%  
Dividends per share (Unadj.) Rs2.0068.00 2.9%  
Dividend yield (eoy) %0.41.5 24.4%  
Book value per share (Unadj.) Rs155.7753.6 20.7%  
Shares outstanding (eoy) m804.5123.03 3,493.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.4 68.2%   
Avg P/E ratio x42.034.7 120.8%  
P/CF ratio (eoy) x18.424.1 76.5%  
Price / Book Value ratio x3.55.9 58.4%  
Dividend payout %15.552.7 29.5%   
Avg Mkt Cap Rs m434,516103,174 421.1%   
No. of employees `00023.03.6 636.0%   
Total wages/salary Rs m26,3383,592 733.2%   
Avg. sales/employee Rs Th6,349.16,537.7 97.1%   
Avg. wages/employee Rs Th1,143.0991.4 115.3%   
Avg. net profit/employee Rs Th449.3819.8 54.8%   
INCOME DATA
Net Sales Rs m146,30223,686 617.7%  
Other income Rs m2,287708 323.0%   
Total revenues Rs m148,58924,394 609.1%   
Gross profit Rs m24,7585,281 468.8%  
Depreciation Rs m13,2291,313 1,007.6%   
Interest Rs m1,59415 10,625.3%   
Profit before tax Rs m12,2224,661 262.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7981,691 106.3%   
Profit after tax Rs m10,3542,970 348.6%  
Gross profit margin %16.922.3 75.9%  
Effective tax rate %14.736.3 40.5%   
Net profit margin %7.112.5 56.4%  
BALANCE SHEET DATA
Current assets Rs m87,37015,673 557.5%   
Current liabilities Rs m33,0816,678 495.4%   
Net working cap to sales %37.138.0 97.7%  
Current ratio x2.62.3 112.5%  
Inventory Days Days8776 114.4%  
Debtors Days Days6222 279.2%  
Net fixed assets Rs m111,5678,098 1,377.7%   
Share capital Rs m1,609230 698.7%   
"Free" reserves Rs m123,64517,088 723.6%   
Net worth Rs m125,25417,356 721.7%   
Long term debt Rs m36,4540-   
Total assets Rs m209,53225,400 824.9%  
Interest coverage x8.7311.7 2.8%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.9 74.9%   
Return on assets %5.711.8 48.5%  
Return on equity %8.317.1 48.3%  
Return on capital %8.526.9 31.6%  
Exports to sales %34.224.5 139.7%   
Imports to sales %8.328.0 29.8%   
Exports (fob) Rs m50,0505,801 862.8%   
Imports (cif) Rs m12,2036,627 184.1%   
Fx inflow Rs m51,0667,145 714.7%   
Fx outflow Rs m17,6786,846 258.2%   
Net fx Rs m33,388299 11,166.7%   
CASH FLOW
From Operations Rs m23,8243,226 738.5%  
From Investments Rs m-13,127-1,555 844.1%  
From Financial Activity Rs m-13,239-1,818 728.2%  
Net Cashflow Rs m-2,478-147 1,685.7%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 60.4 34.4%  
Indian inst/Mut Fund % 12.2 14.4 84.7%  
FIIs % 23.7 14.6 162.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 15,184 1,061.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 19, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS